Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Monocytic, Acute 1Leukemia, Lymphoid 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Cytarabine 23Mitoxantrone 9Etoposide 8Idarubicin 5Filgrastim 5tipifarnib 4fludarabine phosphate 4Daunorubicin 4Cyclophosphamide 4Topotecan 3Sorafenib 3Clofarabine 3Bortezomib 3Azacitidine 3tanespimycin 2alvocidib 2Peripheral Blood Stem Cell Transplantation 2Imatinib Mesylate 2Granulocyte Colony-Stimulating Factor 2Everolimus 2Cladribine 2Carboplatin 2Busulfan 2Arsenic Trioxide 2venetoclax 1veliparib 1trebananib 1sargramostim 1romiplostim 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Monocytic, Acute × romiplostim × Clear all
NCT02046291 2021-06-08

Safety of Romiplostim (Nplate®) Following UCBT

Masonic Cancer Center, University of Minnesota

Phase 1 Completed
21 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoid, Leukemia, Monocytic, Acute, Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡